Drugs / Seneca Valley virus-001
Seneca Valley virus-001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06889493 | May 2025 → Jun 2030 expected | neuroendocrine carcinoma | Peter Hosein, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT01048892 | Sep 2009 → Jun 2013 | adrenal cortex carcinoma, carcinoid tumor, neuroblastoma, retinoblastoma +1 | Children's Oncology Group | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01017601 | Jan 2010 → Jan 2013 | small cell lung carcinoma | Alliance for Clinical Trials in Oncology | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-10-03 | Seneca Therapeutics | Regulatory Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I/II Clinical Study senecatherapeutics.com ↗
Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced today it had received FDA clearance to begin a Phase I/II clinical study utilizing Seneca Valley Virus (“SVV-001”) in combination with a checkpoint inhibitor. |
| 2021-04-12 | Seneca Therapeutics | Results Seneca Therapeutics Reports Late Breaking Information on SVV-001 from the American Association for Cancer Research’s 2021 Annual Meeting senecatherapeutics.com ↗
SVV-001 specifically targets, infects and kills TEM8 positive cancer cells. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-04 | Seneca Therapeutics | Seneca Valley Virus (SVV-001) Clinical Trial Opens at University of Miami senecatherapeutics.com ↗ |
| 2022-10-03 | Seneca Therapeutics | Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I/II Clinical Study senecatherapeutics.com ↗ |
| 2021-04-12 | Seneca Therapeutics | Seneca Therapeutics Reports Late Breaking Information on SVV-001 from the American Association for Cancer Research’s 2021 Annual Meeting senecatherapeutics.com ↗ |
| 2021-02-08 | Seneca Therapeutics | Seneca Therapeutics Expands Product Pipeline Adding Six New SVV-001 Armed Constructs Targeting TEM 8 Expression senecatherapeutics.com ↗ |
| 2020-08-31 | Seneca Therapeutics | Seneca Therapeutics, Inc. Licenses Tumor Endothelial Marker 8 (TEM8) To Enable Better Patient Selection for SVV-001 Therapy senecatherapeutics.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Seneca Valley virus-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01017601 ↗ |
| Known as | NTX-010 | “A virus called Seneca Valley virus-001 (NTX-010) may be able to kill tumor cells without damaging normal cells.” NCT01017601 ↗1“Seneca Valley virus (NTX-010), A Replication-Competent Picornavirus” NCT01048892 ↗ |
| Known as | SVV-001 | “Seneca Valley Virus-001 (SVV-001)” NCT06889493 ↗ |
| Action | Deplete | “A virus called Seneca Valley virus-001 (NTX-010) may be able to kill tumor cells without damaging normal cells.” NCT01017601 ↗ |
| Modality | Other / unclassified | “The Seneca Valley virus (NTX-010) is an oncolytic picornavirus with tropism for SCLC.” PMID 31605793 ↗ Oct 2019 |
| Route | Intravenous | “Given IV” NCT01017601 ↗ |